Tango Therapeutics, Inc. (TNGX) /
The profitability of Tango Therapeutics, Inc. over the past 6 years
Chart Tango Therapeutics, Inc.: operating income, net income, fiscal 2020–2025 Open the chart →Tango Therapeutics, Inc. reported a net loss of $101.59M in fiscal 2025, the latest fiscal year on file. That year it had an operating loss of $111.29M. It reported a loss in all 6 years shown.
Year by year
| Fiscal year | Operating income | Net income |
|---|---|---|
| 2025ended Dec 31, 2025 | -$111.29M | -$101.59M |
| 2024ended Dec 31, 2024 | -$145.59M | -$130.3M |
| 2023ended Dec 31, 2023 | -$114.17M | -$101.74M |
| 2022ended Dec 31, 2022 | -$111.07M | -$108.18M |
| 2021ended Dec 31, 2021 | -$58.19M | -$58.23M |
| 2020ended Dec 31, 2020 | -$52.2M | -$51.97M |
Fiscal years as Tango Therapeutics, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Tango Therapeutics, Inc.
- The revenue of Tango Therapeutics, Inc.
- The cash flow of Tango Therapeutics, Inc.
- The debt of Tango Therapeutics, Inc.
- All of Tango Therapeutics, Inc.'s financials, charted
Companies of a similar size
- MWAMueller Water Products, Inc.
- TNETTRINET GROUP, INC.
- PRIMPrimoris Services Corporation
- BNLBroadstone Net Lease, Inc.
- SMGScotts Miracle-Gro Co
Not investment advice. This page shows what Tango Therapeutics, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.